| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10143095 | Cancer Letters | 2018 | 37 Pages |
Abstract
Our results evidence that FXR activation inhibits tumor-stimulatory activities of CAFs by impacting their mechanical properties and their paracrine signaling repertoire, suggesting that nuclear FXR ligands, by targeting both neoplastic cells and supportive stroma, may represent a promising avenue for the future management of breast cancer.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Ines Barone, Valentina Vircillo, Cinzia Giordano, Luca Gelsomino, Balázs GyÅrffy, Roberta Tarallo, Antonio Rinaldi, Giuseppina Bruno, Antonella Caruso, Francesco Romeo, Daniela Bonofiglio, Sebastiano Andò, Stefania Catalano,